Form 4: Oragenics Director Dunton Awarded 125,000 Stock Options

Oragenics Inc. Director Alan W. Dunton received an award of 125,000 stock options with an exercise price of $0.93, vesting immediately.

Summary

• Alan W. Dunton, a Director of Oragenics Inc. (OGEN), was awarded 125,000 options to purchase shares of the company's Common Stock.
• The transaction date for this award was December 11, 2025.
• The options have an exercise price of $0.93 per share, which was the company's closing price on the date of grant.
• These options vest immediately upon grant and have an expiration date of December 11, 2035.
• The award was made under the Company's 2021 Equity Incentive Plan, as amended, as part of the non-employee director compensation program.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (director option grant) which is generally neutral but can be seen as slightly positive due to aligning director interests with shareholders.

Positives

• The award aligns the director's interests with those of shareholders through equity ownership.
• It represents standard compensation for a non-employee director, indicating a structured governance approach to executive and director remuneration.

Negatives

• The issuance of new options could lead to minor dilution for existing shareholders if exercised, though the amount is not significant enough to cause major concern.

Related Party Transactions

• Award of 125,000 stock options to Alan W. Dunton, a Director of Oragenics Inc., under the company's 2021 Equity Incentive Plan as part of the non-employee director compensation program.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also increased alignment of director's interests with long-term company performance.
• Director (Alan W. Dunton): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Key Dates

Keywords

Oragenics Inc., OGEN, Alan W. Dunton, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4